Article · 5 Oct 2026
Conference abstract
Scaled Average Bioequivalence Statistics for the Non-Statistician
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
F ar too oft en statistics is viewed as a black box into which data enters one side and results exit from the other, with the calculations performed in between considered far too complex or abstract for all but a statistician to understand. Most pharmaceutical scientists have fi nally become comfortable with the 90% confi dence interval approach for average bioequivalence (ABE), at least in non-replicated studies. With the advent of the scaled average bioequivalence (SABE) method, we now have a powerful, but far more confusing statistical approach which requires reference replication. Th e black box associated with this method appears even larger than the one that exists for ABE. To add to the confusion surrounding FDA?s recently disclosed calculations for SABE, the myth continues to spread that all we need to do is calculate the standard 90% confi dence intervals and apply some ?scaled? regulatory limit to the results. A simplifi ed explanation of the SABE calculations, how they relateand do not relate to ABEwill be presented.In addition, minimal statistical concepts familiar to most scientists will be used to explain the inner workings of the SABE black box.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Charles Bon”
